<DOC>
	<DOCNO>NCT00683891</DOCNO>
	<brief_summary>AZUR Pharma receive several report practice psychiatrist prescribe FazaClo show FazaClo patient start lose body weight instead keep gaining , switch clozapine product atypical antipsychotic treatment . Another important clinical observation report doctor considerable reduction hypersalivation FazaClo administration compare antipsychotic treatment . Based finding describe , real need effective safer treatment schizophrenia , AZUR Pharma decide design conduct observational study large number patient take FazaClo prove receive clinical report physician . Better understand evaluation beneficial finding necessary provide physician information improve treatment decision .</brief_summary>
	<brief_title>FazaClo Outcomes Control Schizophrenia ( FOCUS ) Study Survey</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Patients treatmentresistant schizophrenia currently treat Clozaril generic clozapine least 3 month Patients treatmentresistant schizophrenia fail respond adequately treatment least 2 course standard drug treatment schizophrenia , either insufficient effectiveness inability achieve effective dose due intolerable adverse effect drug Males females 18 year age old Females childbearing potential use reliable form contraception Ability comply require WBC/ANC monitoring schedule Ability follow physician 's instruction Signed informed consent patient legal guardian Phenylketonurics Females childbearing potential use reliable form contraception Women pregnant want become pregnant Nursing Patients allergic clozapine othe ingredient contain FazaClo tablet Patients previously experience severe adverse reaction clozapine Patients previously exclude take clozapine due high risk develop white blood cell disorder Clinical significant medical condition physician believe may increase patient 's risk participate int study ( e.g. , severe cardiac disorder , epilepsy ) Concomitant medication may contraindicate FazaClo Patients take FazaCLo within last three month Patients unable comply require WBC/ANC monitoring schedule Patients unable follow physician 's instruction Patients unable unwilling provide Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>FOCUS</keyword>
	<keyword>Weight gain</keyword>
	<keyword>Sialorrhea</keyword>
	<keyword>Treatment refractory schizophrenia</keyword>
	<keyword>FazaClo</keyword>
	<keyword>Treatment resistant schizophrenia</keyword>
	<keyword>clozapine</keyword>
	<keyword>Hypersalivation</keyword>
</DOC>